Three vials filled with human leukocyte interferon.
Find information on thousands of medical conditions and prescription drugs.

Interferon gamma

Interferons (IFNs) are natural proteins produced by the cells of the immune systems of most animals in response to challenges by foreign agents such as viruses, bacteria, parasites and tumor cells. Interferons belong to the large class of glycoproteins known as cytokines. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
Ibuprofen
Idarubicin
Idebenone
IFEX
Iloprost
Imatinib mesylate
Imdur
Imipenem
Imipramine
Imiquimod
Imitrex
Imodium
Indahexal
Indapamide
Inderal
Indocin
Indometacin
Infliximab
INH
Inosine
Intal
Interferon gamma
Intralipid
Invanz
Invirase
Iontocaine
Iotrolan
Ipratropium bromide
Iproniazid
Irbesartan
Iressa
Irinotecan
Isocarboxazid
Isoflurane
Isohexal
Isoleucine
Isomonit
Isoniazid
Isoprenaline
Isordil
Isosorbide
Isosorbide dinitrate
Isosorbide mononitrate
Isotretinoin
Itraconazole
Ivermectin
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Types

In humans, there are 3 major classes of interferon (IFN):

  1. The human type I IFNs consists of 13 different alpha isoforms (subtypes with slightly different specificities) - IFNA(1,2,4,5,6,7,8,10,13,14,16,17,21), and single beta - IFNB1, omega - IFNW1, epsilon - IFNE1 and kappa - IFNK isoforms. Homologous molecules are found in many species, including rats and mice (and most mammals) and have been identified in birds, reptiles, amphibians and fish species. In addition to these IFNs, IFN zeta (limitin) in mice,IFN nu in cats, IFN tau in ruminants and IFN delta in pigs have been identified. All type I IFNs bind to a specific cell surface receptor complex known as IFNAR consisting of IFNAR1 and IFNAR2 chains.
  2. The type II IFNs consists of IFN gamma - IFNG, its sole member. The mature IFNG ligand is an anti-parallel homodimer, and it binds to the IFNG receptor (IFNGR) complex, which is made up of two of each IFNGR1 and IFNGR2 subunits.
  3. The recently discovered 3rd class consists of IFN-lambda with 3 different isoforms - IL29. IL28A, IL28B and signal through a receptor complex consisting of IL10R2 and IFNLR1.

While there are evidence to suggest other signaling mechanisms exist, the JAK-STAT signaling pathway is the best-characterised and commonly accepted IFN signaling pathway.

Principles

In a majority of cases, the production of interferons is induced in response to microbes such as viruses and bacteria and their products (viral glycoproteins, viral RNA, bacterial endotoxin, flagella, CpG DNA), as well as mitogens and other cytokines, for example interleukin-1, interleukin-2, interleukin-12, tumor-necrosis factor and colony-stimulating factor, that are synthesised in the response to the appearance of various antigens in the body. Their metabolism and excretion take place mainly in the liver and kidneys. They hardly pass the placenta and the blood-brain barrier.

Interferon-alpha and -beta are produced by many cell types, including T-cells and B-cells, macrophages, fibroblasts, endothelial cells, osteoblasts and others, and are an important component of the anti-viral response. They stimulate both macrophages and NK cells. Interferons -alpha and -beta are also active against tumors.

Interferon-gamma is involved in the regulation of the immune and inflammatory responses; in humans, there is only one type of interferon-gamma. It is produced in activated T-cells. Interferon-gamma has some anti-viral and anti-tumor effects, but these are generally weak; however, interferon-gamma potentiates the effects of interferon-alpha and interferon-beta. However, interferon-gamma must be released at the site of a tumor in very small doses; at this time, interferon-gamma is not very useful for treating cancer.

Read more at Wikipedia.org


[List your site here Free!]


Interferon gamma-1B inhibits interleukin-4, endothelin-1, and transforming growth factor-beta—induced up-regulation of type I collagen in cellular
From CHEST, 10/1/05 by Osman N. Ozes

PURPOSE: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disease characterized by hyperproliferation of type II epithelial cells in the interstitial space. IPF is thought to result from epithelial cell injury followed by aberrant wound healing and excessive accumulation of collagen, which lead to the development of fibroblastic foci or lesions. Interleukin (IL)-4, endothelin (ET)-1, and transforming growth factor beta (TGF-[beta]) all induce transcriptional up-regulation of type I collagen, suggesting that all could enhance the accumulation of extracellular matrix (ECM) during the development of IPF. Interferon gamma-1b (IFN-[gamma] 1b) has demonstrated anti-infective properties and is currently indicated for use in chronic granulomatous disease and malignant osteopetrosis. It is also under clinical study for the treatment of IPF, for which it may offer a survival benefit (Raghu G, Brown KK, Bradford WZ, et al. N Engl J Med. 2004;350(2):125-133).

METHODS: To evaluate the effect of IFN-[gamma] 1b un type I collagen synthesis, we studied its effect on IL-4, ET-1, and TGF-[beta]--induced type I collagen synthesis in human lung fibroblasts. Secreted collagen levels were determined by the ratio of total and collagenase-stable [sup.3]H-labeled protein in cell culture supernatants.

RESULTS: Relative to untreated cells, 5 ng/mL IL-4, ET-1, or TGF-[beta] induced the expression of type I collagen by 42%, 58%, and 78%, respectively (p < 0.05). The collagen-inducing activities of IL-4, ET-1, and TGF-[beta] were additive; collagen secretion increased 2.2-fold when cells were stimulated with all three (p < 0.05). A 5 ng/mL IFN-[gamma] 1b dose reduced ET-1 and IL-4-stimulated collagen production to a level at or below that observed without stimulation; TGF-[beta]-induced collagen secretion was decreased by 17% (p < 0.05). IFN-[gamma] 1b was also effective in reducing collagen production from cells treated with any combination of IL-4, ET-1, and TGF-[beta]. In cells treated with all three, IFN-[gamma] 1b reduced collagen secretion by 18% (p < 0.05).

CONCLUSION: These results indicate that IFN-[gamma] 1b may modulate fibrotic microenvironments that are associated with pathogenesis in IPF.

CLINICAL IMPLICATIONS: Our results support ongoing clinical research.

DISCLOSURE: Osman Ozes, Shareholder ; Employee All authors are employees of InterMune, Inc.; Product/procedure/technique that is considered research and is not yet approved for any purpose.

Osman N. Ozes PhD * Lawrence M. Blatt PhD Scott Seiwert PhD InterMune, Inc., Brisbane, CA

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Interferon gamma
Home Contact Resources Exchange Links ebay